TL;DR: The cannabis sector enters the July 12–18 trading week with constructive momentum, as the MSOS ETF held its multi-week advance through Friday’s close and the Q2 2026 earnings calendar begins filling with multi-operator reports. Regulatory positioning around Schedule III rulemaking remains a background tailwind, while near-term price action will be dictated by earnings guidance and broader macro sentiment heading into mid-July.
Market Analysis
The AdvisorShares Pure US Cannabis ETF (MSOS) closed the week ending July 11, 2026, consolidating near recent highs after a multi-session rally that carried the fund approximately 6–8% off its late-June lows. Volume patterns through the week were notably constructive, with accumulation days outpacing distribution as institutional participation appeared to increase ahead of the Q2 reporting cycle.
Large-cap U.S. multi-state operators (MSOs) tracked in lockstep with the broader sector move. Green Thumb Industries (GTBIF), Curaleaf Holdings (CURLF), and Cresco Labs (CRLBF) all posted weekly gains, while Trulieve Cannabis (TCNNF) showed relative strength driven by its dominant Florida retail position. Trading desks entering the weekend were tilted cautiously constructive — holding core long positions but trimming speculative exposure ahead of a weekend with limited catalysts.
Canadian licensed producers presented a more mixed picture. Tilray Brands (TLRY) and Organigram Holdings (OGI) remain range-bound as German cannabis market developments and U.S. strategic optionality continue to be debated by the analyst community. Aurora Cannabis (ACB) is testing key technical support as balance sheet concerns persist despite operational improvements in its European medical segment.
Regulatory and Market Context
The Schedule III reclassification process continues to serve as the dominant regulatory backdrop for U.S. cannabis equities. The DEA’s administrative review is proceeding through its procedural phases, with industry observers watching for any formal rulemaking publication that would trigger the next stage of comment periods. Legal experts tracking the process suggest the timeline extends into late 2026 or early 2027 before any reclassification takes effect — meaning the current market is pricing regulatory optionality rather than near-term operational change.
State-level market dynamics continue to diverge. Illinois and New Jersey remain high-growth markets for operators with concentrated exposure, while oversupplied markets in Colorado and Michigan continue to compress wholesale flower prices and pressure operator margins. Florida remains the most closely watched single-state market given its size, Trulieve’s dominance, and ongoing legislative discourse around adult-use expansion.
For investors monitoring sector positioning, the cannabis stock tracker provides a live view of key MSO and LP price movements, ETF flows, and earnings date calendars to track the Q2 reporting season as it unfolds.
Conclusion
The week ahead (July 14–18) will be defined by whether the sector can sustain its recent advance in the absence of major catalysts. With the broader equity market navigating mixed macro signals and the cannabis earnings calendar accelerating toward late July and early August, the most productive positioning strategy for institutional participants may be selective accumulation in names with near-term earnings visibility. GTBIF reports around August 4, Curaleaf around August 5, and Canopy Growth around August 7 — each representing potential near-term re-rating events. Positioning ahead of those reports is likely to dominate sector narrative through the remainder of July.